Cargando…

A novel mechanism for the anticancer activity of aspirin and salicylates

Epidemiological studies indicate that long-term aspirin usage reduces the incidence of colorectal cancer (CRC) and may protect against other non-CRC associated adenocarcinomas, including oesophageal cancer. A number of hypotheses have been proposed with respect to the molecular action of aspirin and...

Descripción completa

Detalles Bibliográficos
Autores principales: Bashir, Asma’u I.J., Kankipati, Chandra S., Jones, Sarah, Newman, Robert M., Safrany, Stephen T., Perry, Christopher J., Nicholl, Iain D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411351/
https://www.ncbi.nlm.nih.gov/pubmed/30720135
http://dx.doi.org/10.3892/ijo.2019.4701
_version_ 1783402378712580096
author Bashir, Asma’u I.J.
Kankipati, Chandra S.
Jones, Sarah
Newman, Robert M.
Safrany, Stephen T.
Perry, Christopher J.
Nicholl, Iain D.
author_facet Bashir, Asma’u I.J.
Kankipati, Chandra S.
Jones, Sarah
Newman, Robert M.
Safrany, Stephen T.
Perry, Christopher J.
Nicholl, Iain D.
author_sort Bashir, Asma’u I.J.
collection PubMed
description Epidemiological studies indicate that long-term aspirin usage reduces the incidence of colorectal cancer (CRC) and may protect against other non-CRC associated adenocarcinomas, including oesophageal cancer. A number of hypotheses have been proposed with respect to the molecular action of aspirin and other non-steroidal anti-inflammatory drugs in cancer development. The mechanism by which aspirin exhibits toxicity to CRC has been previously investigated by synthesising novel analogues and derivatives of aspirin in an effort to identify functionally significant moieties. Herein, an early effect of aspirin and aspirin-like analogues against the SW480 CRC cell line was investigated, with a particular focus on critical molecules in the epidermal growth factor (EGF) pathway. The present authors proposed that aspirin, diaspirin and analogues, and diflunisal (a salicylic acid derivative) may rapidly perturb EGF and EGF receptor (EGFR) internalisation. Upon longer incubations, the diaspirins and thioaspirins may inhibit EGFR phosphorylation at Tyr1045 and Tyr1173. It was additionally demonstrated, using a qualitative approach, that EGF internalisation in the SW480 cell line may be directed to endosomes by fumaryldiaspirin using early endosome antigen 1 as an early endosomal marker and that EGF internalisation may also be perturbed in oesophageal cell lines, suggestive of an effect not only restricted to CRC cells. Taken together and in light of our previous findings that the aspirin-like analogues can affect cyclin D1 expression and nuclear factor-κB localisation, it was hypothesized that aspirin and aspirin analogues significantly and swiftly perturb the EGFR axis and that the protective activity of aspirin may in part be explained by perturbed EGFR internalisation and activation. These findings may also have implications in understanding the inhibitory effect of aspirin and salicylates on wound healing, given the critical role of EGF in the response to tissue trauma.
format Online
Article
Text
id pubmed-6411351
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-64113512019-03-19 A novel mechanism for the anticancer activity of aspirin and salicylates Bashir, Asma’u I.J. Kankipati, Chandra S. Jones, Sarah Newman, Robert M. Safrany, Stephen T. Perry, Christopher J. Nicholl, Iain D. Int J Oncol Articles Epidemiological studies indicate that long-term aspirin usage reduces the incidence of colorectal cancer (CRC) and may protect against other non-CRC associated adenocarcinomas, including oesophageal cancer. A number of hypotheses have been proposed with respect to the molecular action of aspirin and other non-steroidal anti-inflammatory drugs in cancer development. The mechanism by which aspirin exhibits toxicity to CRC has been previously investigated by synthesising novel analogues and derivatives of aspirin in an effort to identify functionally significant moieties. Herein, an early effect of aspirin and aspirin-like analogues against the SW480 CRC cell line was investigated, with a particular focus on critical molecules in the epidermal growth factor (EGF) pathway. The present authors proposed that aspirin, diaspirin and analogues, and diflunisal (a salicylic acid derivative) may rapidly perturb EGF and EGF receptor (EGFR) internalisation. Upon longer incubations, the diaspirins and thioaspirins may inhibit EGFR phosphorylation at Tyr1045 and Tyr1173. It was additionally demonstrated, using a qualitative approach, that EGF internalisation in the SW480 cell line may be directed to endosomes by fumaryldiaspirin using early endosome antigen 1 as an early endosomal marker and that EGF internalisation may also be perturbed in oesophageal cell lines, suggestive of an effect not only restricted to CRC cells. Taken together and in light of our previous findings that the aspirin-like analogues can affect cyclin D1 expression and nuclear factor-κB localisation, it was hypothesized that aspirin and aspirin analogues significantly and swiftly perturb the EGFR axis and that the protective activity of aspirin may in part be explained by perturbed EGFR internalisation and activation. These findings may also have implications in understanding the inhibitory effect of aspirin and salicylates on wound healing, given the critical role of EGF in the response to tissue trauma. D.A. Spandidos 2019-01-29 /pmc/articles/PMC6411351/ /pubmed/30720135 http://dx.doi.org/10.3892/ijo.2019.4701 Text en Copyright: © Bashir et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Bashir, Asma’u I.J.
Kankipati, Chandra S.
Jones, Sarah
Newman, Robert M.
Safrany, Stephen T.
Perry, Christopher J.
Nicholl, Iain D.
A novel mechanism for the anticancer activity of aspirin and salicylates
title A novel mechanism for the anticancer activity of aspirin and salicylates
title_full A novel mechanism for the anticancer activity of aspirin and salicylates
title_fullStr A novel mechanism for the anticancer activity of aspirin and salicylates
title_full_unstemmed A novel mechanism for the anticancer activity of aspirin and salicylates
title_short A novel mechanism for the anticancer activity of aspirin and salicylates
title_sort novel mechanism for the anticancer activity of aspirin and salicylates
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411351/
https://www.ncbi.nlm.nih.gov/pubmed/30720135
http://dx.doi.org/10.3892/ijo.2019.4701
work_keys_str_mv AT bashirasmauij anovelmechanismfortheanticanceractivityofaspirinandsalicylates
AT kankipatichandras anovelmechanismfortheanticanceractivityofaspirinandsalicylates
AT jonessarah anovelmechanismfortheanticanceractivityofaspirinandsalicylates
AT newmanrobertm anovelmechanismfortheanticanceractivityofaspirinandsalicylates
AT safranystephent anovelmechanismfortheanticanceractivityofaspirinandsalicylates
AT perrychristopherj anovelmechanismfortheanticanceractivityofaspirinandsalicylates
AT nicholliaind anovelmechanismfortheanticanceractivityofaspirinandsalicylates
AT bashirasmauij novelmechanismfortheanticanceractivityofaspirinandsalicylates
AT kankipatichandras novelmechanismfortheanticanceractivityofaspirinandsalicylates
AT jonessarah novelmechanismfortheanticanceractivityofaspirinandsalicylates
AT newmanrobertm novelmechanismfortheanticanceractivityofaspirinandsalicylates
AT safranystephent novelmechanismfortheanticanceractivityofaspirinandsalicylates
AT perrychristopherj novelmechanismfortheanticanceractivityofaspirinandsalicylates
AT nicholliaind novelmechanismfortheanticanceractivityofaspirinandsalicylates